전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved56 programs
ADCCurated CoreFDAAbbVieDM4 (maytansinoid, tubulin …Approved

mirvetuximab soravtansine (Elahere, IMGN853, mirvetuximab-soravtansine-gynx)

FRα-positive platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer · FRα (folate receptor alpha)

#FRfolatereceptoralpha#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 32Status Approved
AntibodyLimited DatastalePENG YUANPhase 2

QL1706 (Iparomlimab and Tuvonralimab, Iparomlimab and Tuvonralimab (QL1706))

Platinum Resistant Ovarian Cancer; Platinum Refractory Epithelial Ovarian Cancer · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#Popular#monoclonal-antibody+4
Trials 143Status Recruiting
CGTLimited DatastaleFundamenta Therapeutics, Ltd.Phase 1

Chimeric Antigen Receptor T-cells (Chimeric Antigen Receptor T-cells)

Leukemia, Acute Lymphocytic (ALL); Leukemia, Acute Myelogenous (AML) · Platinum-Resistant Ovarian Carcinoma

#Platinum-ResistantOvarianCarcino#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 93Status Active
CGTStandard DatabasestaleMedigene AGPhase 2

Lymphodepletion (Lymphodepletion)

Epithelial Ovarian Cancer; Gastro-esophageal Junction Cancer · FRα

#FR#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 60Status Discontinued
CGTLimited DatastaleMedigene AGPhase 1

MDG1015 (TCR-T cells, TCR-T cells (MDG1015))

Epithelial Ovarian Cancer; Gastro-esophageal Junction Cancer · Epithelial Ovarian Cancer

#EpithelialOvarianCancer#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 60Status Recruiting
AntibodyLimited DatastaleRegeneronPhase 2

Cemiplimab + Fianlimab [Fixed Dose Combination (FDC, Cemiplimab + Fianlimab [Fixed Dose Combination, Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)])

Ovarian Cancer; Fallopian Tube Cancer · Ovarian Cancer

#OvarianCancer#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 59Status Recruiting
CGTLimited DatastaleAllife Medical Science and Tech…Phase 2

Cytokine-induced killer cells (Cytokine-induced killer cells)

Ovarian Carcinoma · Cholangiocarcinoma

#Cholangiocarcinoma#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 56Status Recruiting
AntibodyLimited DatastaleRegeneron PharmaceuticalsPhase 2

Fianlimab (Fianlimab)

Ovarian Cancer; Fallopian Tube Cancer · NSCLC

#NSCLC#Antibody#Phase2#monoclonal-antibody#OvarianCancer+3
Trials 39Status Recruiting
AntibodyLimited DatastaleMerck Sharp & Dohme LLCPhase 3

H1 receptor antagonist (H1 receptor antagonist)

Ovarian Cancer; Fallopian Tube Cancer · Lung Neoplasm Malignant

#LungNeoplasmMalignant#Antibody#Phase3#monoclonal-antibody#OvarianCancer+3
Trials 31Status Recruiting
AntibodyLimited DatastaleMerck Sharp & Dohme LLCPhase 3

H2 receptor antagonist (H2 receptor antagonist)

Ovarian Cancer; Fallopian Tube Cancer · Lung Neoplasm Malignant

#LungNeoplasmMalignant#Antibody#Phase3#monoclonal-antibody#OvarianCancer+2
Trials 31Status Recruiting
CGTLimited DatastaleDutch Cancer SocietyPhase 1

UCB-NK cells (UCB-NK cells)

Recurrent Ovarian Carcinoma; Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma

#RecurrentOvarianCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 16Status Active
AntibodyLimited DatastaleAstraZenecaPhase 1

durvalumab (Imfinzi, Administration of ceralasertib and durvalumab)

Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer · Adv Solid Malig - H&N SCC, ATM Pro / Def

#AdvSolidMalig-HNSCCATMProDef#Antibody#Phase1#monoclonal-antibody#AdvSolidMalig-HNSCC+3
Trials 12Status Recruiting
CGTLimited DatastaleHrain Biotechnology Co., Ltd.Phase 1

anti-MESO CAR-T cells (anti-MESO CAR-T cells)

Ovarian Cancer · Ovarian Cancer

#OvarianCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 12Status Active
CGTLimited DatastaleBeijing BiotechPhase 2

Dual-target CAR-NK cell product (Dual-target CAR-NK cell product)

Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 10Status Recruiting
AntibodyLimited DatastaleARCAGYPhase 2

Ubamatamab (Ubamatamab)

Ovarian Cancer · Recurrent Ovarian Cancer

#RecurrentOvarianCancer#Antibody#Phase2#monoclonal-antibody#OvarianCancer+1
Trials 7Status Recruiting
ADCStandard DatabasestaleAbbViePhase 3

Mirvetuximab soravtansine plus Bevacizumab (Mirvetuximab soravtansine plus Bevacizumab)

Ovarian Cancer; Peritoneal Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase3#antibody-drug-conjugate#PeritonealCancer+1
Trials 6Status Recruiting
ADCLimited DatastaleSeagen Inc.Phase 2

cBR96-Doxorubicin Immunoconjugate (SGN-15, SGN-15 (cBR96-Doxorubicin Immunoconjugate))

Prostatic Neoplasms · Ovarian Neoplasms

#OvarianNeoplasms#ADC#Phase2#antibody-drug-conjugate#ProstaticNeoplasms+1
Trials 5Status Active
AntibodyLimited DatastaleXencor, Inc.Phase 2

Vudalimab (Vudalimab)

Ovarian Cancer; Clear Cell Carcinoma · Castration-Sensitive Prostate Carcinoma

#Castration-SensitiveProstateCarc#Antibody#Phase2#monoclonal-antibody#OvarianCancer+2
Trials 5Status Discontinued
AntibodyCurated CorestaleSutro Biopharma, Inc.Phase 3

Luveltamab tazevibulin (Luveltamab tazevibulin)

Ovarian Cancer; Epithelial Ovarian Cancer · Ovarian Cancer

#OvarianCancer#Antibody#Phase3#BioJungboMoa-pick#monoclonal-antibody+2
Trials 3Status Discontinued
CGTLimited DatastalePeking UniversityPhase 1

B7H3 CAR-γδT cells (B7H3 CAR-γδT cells)

Advanced Solid Tumors; Ovarian Cancers · Advanced Solid Tumors

#AdvancedSolidTumors#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 2Status Recruiting

1 / 3 pages

← PreviousNext →